ProCE Banner Activity

MITHIC-FL1: Phase II Study of Single-Agent Mosunetuzumab in Patients With Newly Diagnosed Follicular Lymphoma

Conference Coverage
Slideset

Primary analysis of the phase II MITHIC-FL1 trial of subcutaneous mosunetuzumab monotherapy demonstrated a high overall response rate, a high 1-year overall survival rate, and a manageable safety profile when used as first-line therapy for patients with follicular lymphoma.

Released: December 09, 2024

Expiration: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation